Dasatinib Tablets 50 Mg – Generic Sprycel

Dasatinib Tablets 50 Mg – Generic Sprycel

Dasatinib Tablets 50 Mg – Generic Sprycel is a targeted anticancer medication used in the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It belongs to the class of tyrosine kinase inhibitors (TKIs), which block abnormal proteins responsible for cancer cell growth. This lower-strength formulation is often used for dose adjustments, maintenance therapy, or in patients who require reduced dosing due to side effects. In oncology treatment strategies, higher strengths such as Dasatinib Tablets 100 Mg – Generic Sprycel are commonly used for standard dosing, while chemotherapy agents like Capecitabine Tablets 500 Mg – Generic Xeloda are utilized in different cancer indications such as breast and colorectal cancers.

Mechanism of Action

Tyrosine Kinase Inhibition

Dasatinib Tablets 50 Mg works by inhibiting the BCR-ABL tyrosine kinase enzyme produced by the Philadelphia chromosome, which drives leukemia cell growth.

Blocking Cancer Cell Growth

By targeting this pathway, the drug prevents cancer cells from multiplying and promotes their destruction. For detailed research insights, refer to National Cancer Institute (NCI) and for safety information, consult Mayo Clinic – Dasatinib Drug Information.

Medical Uses

Dasatinib Tablets 50 Mg – Generic Sprycel is used in:

• Chronic myeloid leukemia (CML)
• Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)

It is often prescribed when dose adjustments are required or for long-term disease management.

Dosage and Administration

Dasatinib Tablets 50 Mg is typically taken once daily, with or without food, as prescribed by an oncologist. The dosage is adjusted based on patient response and tolerability. In treatment planning, Dasatinib Tablets 100 Mg – Generic Sprycel may be used as a standard dose, while therapies like Capecitabine Tablets 500 Mg – Generic Xeloda are used in different cancer types depending on the clinical scenario.

Clinical Effectiveness

Clinical studies have shown that Dasatinib effectively improves response rates and disease control in patients with CML and Ph+ ALL. The 50 mg dose is particularly useful for maintaining treatment while minimizing side effects.

Safety and Side Effects

Common Side Effects

• Fatigue
• Nausea
• Headache
• Fluid retention

Serious Risks

• Low blood cell counts
• Bleeding complications
• Pleural effusion (fluid around the lungs)
• Heart rhythm changes

Regular monitoring is essential during treatment. For more details, refer to Mayo Clinic – Dasatinib Drug Information.

Contraindications and Precautions

Dasatinib Tablets 50 Mg should be used with caution in:

• Patients with heart disease
• Individuals with liver impairment
• Patients at risk of bleeding disorders

It should not be used during pregnancy unless prescribed.

Drug Interactions

Dasatinib Tablets 50 Mg may interact with CYP3A4 inhibitors or inducers, antacids, and other anticancer medications. Patients should inform their healthcare provider about all medicines they are taking. For research-based insights, refer to National Cancer Institute (NCI).

FAQs